Loading
Intensity Therapeutics
Intensity Therapeutics is a Connecticut biotech whose INT230-6 is injected straight into tumours with a penetration enhancer that spreads chemotherapy through the whole mass and triggers an immune response.
Also called: Intensity Therapeutics, Inc.NASDAQ:INTS
Overview
Intensity Therapeutics developed INT230-6, an intratumoural formulation of cisplatin and vinblastine with the amphiphilic molecule SHAO, which disperses the drugs through the tumour and into cells. Killing the tumour in place releases antigens that prime systemic immunity. The company is running the phase 3 INVINCIBLE-3 trial in soft tissue sarcoma and the phase 2 INVINCIBLE-4 trial in presurgical triple-negative breast cancer.
Headquarters
Shelton, Connecticut, US
Scorecard
All companies#398of 1245 companies, score 9
- phase 3 +3
- modalities +2
- registry trials +4
0 approved, 1 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:INTS
Stage
Public
Founded
2012
Products
1Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
INT230-6 is an experimental investigational agent whose form is not stated in the registry from Intensity Therapeutics in phase 3 trials for sarcomas, with its target not yet stated publicly.
Connected
2drugs
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
intensitytherapeutics.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 193 company-less drugs to their makers and add 74 ma… · diff · file
Sourced, not expert-reviewed